Miklos Salgo

4.4k total citations · 1 hit paper
53 papers, 3.2k citations indexed

About

Miklos Salgo is a scholar working on Infectious Diseases, Virology and Genetics. According to data from OpenAlex, Miklos Salgo has authored 53 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Infectious Diseases, 29 papers in Virology and 8 papers in Genetics. Recurrent topics in Miklos Salgo's work include HIV/AIDS drug development and treatment (31 papers), HIV Research and Treatment (29 papers) and HIV/AIDS Research and Interventions (18 papers). Miklos Salgo is often cited by papers focused on HIV/AIDS drug development and treatment (31 papers), HIV Research and Treatment (29 papers) and HIV/AIDS Research and Interventions (18 papers). Miklos Salgo collaborates with scholars based in United States, United Kingdom and Switzerland. Miklos Salgo's co-authors include Ralph DeMasi, Jain Chung, Michael Greenberg, John Delehanty, Thomas J. Matthews, Gérald Oster, Dani P. Bolognesi, Calvin Cohen, Peter J. Piliero and Jacob Lalezari and has published in prestigious journals such as New England Journal of Medicine, Nature Reviews Drug Discovery and Clinical Infectious Diseases.

In The Last Decade

Miklos Salgo

52 papers receiving 3.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South America

2003 716 citations Jacob Lalezari, Keith Henry et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Miklos Salgo

Since Specialization

Citations

This map shows the geographic impact of Miklos Salgo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Miklos Salgo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Miklos Salgo more than expected).

Fields of papers citing papers by Miklos Salgo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Miklos Salgo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Miklos Salgo. The network helps show where Miklos Salgo may publish in the future.

Co-authorship network of co-authors of Miklos Salgo

This figure shows the co-authorship network connecting the top 25 collaborators of Miklos Salgo. A scholar is included among the top collaborators of Miklos Salgo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Miklos Salgo. Miklos Salgo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	COVID-19: Zinc and Angiotensin-Converting Enzyme 2 (ACE2) Deficiencies as Determinants of Risk and Severity of Disease: A Narrative Review 2021 ·Infectious Diseases and Therapy ·Miklos Salgo	10
2	Thorough QT/QTc Study of Ritonavir‐Boosted Saquinavir Following Multiple‐Dose Administration of Therapeutic and Supratherapeutic Doses in Healthy Participants 2011 ·The Journal of Clinical Pharmacology ·Xiaoping Zhang, Paul Jordan, (unknown), Miklos Salgo, Rana Abu Farha, Stanley J. Kolis, (unknown)	19
3	Elevated ethyl methanesulfonate (EMS) in nelfinavir mesylate (Viracept®, Roche): overview 2009 ·AIDS Research and Therapy ·Anton Pozniak, Lutz Müller, Miklos Salgo, Judith K. Jones, Peter J. Larson, David Tweats	16
4	Adherence to Enfuvirtide and Its Impact on Treatment Efficacy 2008 ·AIDS Research and Human Retroviruses ·Jürgen K. Rockstroh, Edwin DeJesus, (unknown), Cynthia Wat, A Bertasso, Emily Labriola–Tompkins, (unknown), (unknown), (unknown), Timothy D. Wilkinson, James Thommes, Lucy Rowell, Ralph DeMasi, Miklos Salgo	4
5	Efficacy and Safety of 48 Weeks of Enfuvirtide 180 mg Once-Daily Dosing Versus 90 mg Twice-Daily Dosing in HIV-Infected Patients 2008 ·HIV Clinical Trials ·David H. Wright, (unknown), Eliot Godofsky, Sharon Walmsley, Emily Labriola–Tompkins, (unknown), (unknown), (unknown), (unknown), Jain Chung, Lucy Rowell, Ralph DeMasi, Neil M.H. Graham, Miklos Salgo	10
6	Enfuvirtide Does Not Require Dose Adjustment in Patients With Chronic Kidney Failure 2008 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Pablo Tebas, (unknown), Christopher Lucasti, Gary Richmond, Eliot Godofsky, Indravadan H. Patel, (unknown), Claire F. Evans, Lucy Rowell, Miklos Salgo	15
7	A randomized, controlled study evaluating an induction treatment strategy in which enfuvirtide was added to an oral, highly active antiretroviral therapy regimen in treatment-experienced patients: the INTENSE study 2008 ·Journal of Antimicrobial Chemotherapy ·Bonaventura Clotet, Amedeo Capetti, Luis Enrique Soto-Ramírez, José M. Gatell, Lucy Rowell, Miklos Salgo, Jonathan Schapiro	5
8	Switching from a Toxicity-Causing Antiretroviral to Enfuvirtide in Patients with HIV: The SWITCH TOX Study 2008 ·HIV Clinical Trials ·Adrian Streinu‐Cercel, Miguel Górgolas, Markus Müller, Joaquín Portilla, Sorin Rugină, Wulf O. Böcher, Schlomo Staszewski, (unknown), Lucy Rowell, Miklos Salgo, Matthias Stoll	3
9	Seeking Ethical Designs for HIV Clinical Trials in Treatment-Experienced Patients: An Industry Perspective 2006 ·AIDS Research and Human Retroviruses ·Douglas L. Mayers, Jain Chung, Veronika Kohlbrenner, David B. Hall, Ralph DeMasi, Dietmar Neubacher, Neil Buss, Miklos Salgo	1
10	Week-12 Response to Therapy as a Predictor of Week 24, 48, and 96 Outcome in Patients Receiving the HIV Fusion Inhibitor Enfuvirtide in the T-20 versus Optimized Regimen Only (TORO) Trials 2006 ·Clinical Infectious Diseases ·F. Raffi, Christine Katlama, Michael S. Saag, Mark C. Wilkinson, Jain Chung, (unknown), Miklos Salgo	37
11	Characterization of Envelope Glycoprotein gp41 Genotype and Phenotypic Susceptibility to Enfuvirtide at Baseline and on Treatment in the Phase III Clinical Trials TORO-1 and TORO-2 2006 ·AIDS Research and Human Retroviruses ·Thomas Melby, Prakash Sista, Ralph DeMasi, Theo N. Kirkland, N. A. Roberts, Miklos Salgo, Gabrielle Heilek‐Snyder, (unknown), Thomas J. Matthews, Michael Greenberg	57
12	HIV fusion and its inhibition in antiretroviral therapy 2004 ·Reviews in Medical Virology ·Michael Greenberg, Nick Cammack, Miklos Salgo, Lynn Smiley	56
13	Safety, tolerability, and plasma pharmacokinetics of high-strength formulations of enfuvirtide (T-20) in treatment-experienced HIV-1-infected patients 2003 ·Journal of Clinical Virology ·David A. Wheeler, Jacob Lalezari, J Michael Kilby, Joseph Wheat, John Delehanty, Ralph DeMasi, Indravadan H. Patel, Miklos Salgo	18
14	Enfuvirtide (T‐20) Cross‐Reactive Glycoprotein 41 Antibody Does Not Impair the Efficacy or Safety of Enfuvirtide 2003 ·The Journal of Infectious Diseases ·Sharon Walmsley, Keith Henry, Christine Katlama, Mark Nelson, Antonella Castagna, Jacques Reynes, Bonaventura Clotet, James Hoi Po Hui, Miklos Salgo, Ralph DeMasi, John Delehanty	29
15	Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South America breakdown → 2003 ·New England Journal of Medicine ·Jacob Lalezari, Keith Henry, Mary O’Hearn, Joan Montaner, Peter J. Piliero, Benoît Trottier, Sharon Walmsley, Calvin Cohen, Daniel R. Kuritzkes, Joseph J. Eron, Jain Chung, Ralph DeMasi, (unknown), (unknown), John Delehanty, Miklos Salgo	716
16	Guillain‐Barre Syndrome Associated with Immune Reconstitution 2003 ·Clinical Infectious Diseases ·Peter J. Piliero, Douglas G. Fish, Sandra L. Preston, (unknown), Tosca Kinchelow, Miklos Salgo, Qian Jiang, George L. Drusano	54
17	COMPARATIVE TRIAL OF TWO DOSAGES OF ZALCITABINE IN ZIDOVUDINE-EXPERIENCED CHILDREN WITH ADVANCED HUMAN IMMUNODEFICIENCY VIRUS DISEASE 1997 ·The Pediatric Infectious Disease Journal ·Stephen A. Spector, Suzette Blanchard, Diane W. Wara, James M. Oleske, Kenneth McIntosh, David S. Hodes, Wayne M. Dankner, Miklos Salgo, James McNamara	5
18	Evaluation of Pharmacokinetics, Safety, Tolerance, and Activity of Combination of Zalcitabine and Zidovudine in Stable, Zidovudine‐Treated Pediatric Patients with Human Immunodeficiency Virus Infection 1997 ·The Journal of Infectious Diseases ·Saroj Bakshi, Paula Britto, Edmund V. Capparelli, Lynne Mofenson, (unknown), Suraiya Rasheed, David Schoenfeld, Bonnie Zimmer, Yitzchak Frank, Ram Yogev, Eleanor Jiménez, Miklos Salgo, (unknown), Savita Pahwa	19
19	Safety and tolerability of zalcitabine (ddC) in patients with AIDS or advanced AIDS-related complex in the European expanded access programme 1996 ·International Journal of Antimicrobial Agents ·Graeme Moyle, A. Göll, S. Snape, (unknown), (unknown), (unknown), Miklos Salgo	8
20	In Vitro Assessment of Antimicrobial Agents Against Toxoplasma gondii 1988 ·The Journal of Infectious Diseases ·Carol Harris, Miklos Salgo, Herbert B. Tanowitz, Murray Wittner	62

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact